| 40.82 0.42 (1.04%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 52.28 |
1-year : | 57.32 |
| Resists | First : | 44.76 |
Second : | 49.08 |
| Pivot price | 41.37 |
|||
| Supports | First : | 37.77 | Second : | 31.43 |
| MAs | MA(5) : | 39.53 |
MA(20) : | 42.42 |
| MA(100) : | 57.89 |
MA(250) : | 69.95 |
|
| MACD | MACD : | -2.3 |
Signal : | -2.3 |
| %K %D | K(14,3) : | 30.9 |
D(3) : | 20.5 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 95.01 | Low : | 37.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ QDEL ] has closed above bottom band by 42.9%. Bollinger Bands are 33.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 40.89 - 41.06 | 41.06 - 41.22 |
| Low: | 38.78 - 38.96 | 38.96 - 39.13 |
| Close: | 40.52 - 40.81 | 40.81 - 41.09 |
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Wed, 24 Apr 2024
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses ... - GlobeNewswire
Tue, 23 Apr 2024
QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Corporation Investors Can ... - AccessWire
Mon, 22 Apr 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho ... - PR Newswire
Mon, 22 Apr 2024
QuidelOrtho Corporation (QDEL) Investor Notice: Robbins LLP Reminds Stockholders of the QuidelOrtho Corporation ... - Business Wire
Mon, 22 Apr 2024
QDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a ... - PR Newswire
Mon, 22 Apr 2024
QUIDELORTHO CORPORATION (NASDAQ: QDEL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds QuidelOrtho ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 67 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 100.3 (%) |
| Shares Short | 2,250 (K) |
| Shares Short P.Month | 2,370 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 75.05 |
| Profit Margin | -0.4 % |
| Operating Margin | 13.4 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | -0.3 % |
| Qtrly Rev. Growth | -14.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 44.85 |
| EBITDA (p.s.) | 11 |
| Qtrly Earnings Growth | -77.1 % |
| Operating Cash Flow | 280 (M) |
| Levered Free Cash Flow | 336 (M) |
| PE Ratio | -272.14 |
| PEG Ratio | 2.2 |
| Price to Book value | 0.54 |
| Price to Sales | 0.91 |
| Price to Cash Flow | 9.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|